Clinical Profile of Suvorexant (MK-4305), an Orexin Receptor Antagonist, in Patients with Primary Insomnia: Results From Phase-3 Trials

被引：0
|
作者：
Herring, W. Joseph [1 ]
机构：
[1] Merck Res Labs, Kenilworth, NJ USA
来源：
BIOLOGICAL PSYCHIATRY | 2014年 / 75卷 / 09期
关键词：
Insomnia; Suvorexant; orexin; sleep; polysomnography;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
107
引用
收藏
页码：35S / 35S
页数：1
相关论文
共 50 条
  • [1] EEG POWER SPECTRAL PROFILE OF THE OREXIN RECEPTOR ANTAGONIST SUVOREXANT (MK-4305) IN PATIENTS WITH PRIMARY INSOMNIA AND IN HEALTHY SUBJECTS
    Herring, W. J.
    Ma, J.
    Snyder, E.
    Svetnik, V
    Hutzelmann, J.
    Liu, K.
    Lines, C.
    Roth, T.
    Michelson, D.
    [J]. SLEEP, 2012, 35 : A222 - A222
  • [2] Power Spectral Profile of the Orexin Receptor Antagonist Suvorexant (MK-4305) in Primary Insomnia Patients and Healthy-Subjects
    Herring, William J.
    Ma, Junshui
    Snyder, Ellen
    Svetnik, Vladimir
    Hutzelmann, Jill
    Liu, Kenneth
    Lines, Christopher
    Roth, Thomas
    Michelson, David
    [J]. BIOLOGICAL PSYCHIATRY, 2012, 71 (08) : 297S - 298S
  • [3] EFFICACY AND TOLERABILITY OF THE DUAL OREXIN RECEPTOR ANTAGONIST MK-4305 IN PATIENTS WITH PRIMARY INSOMNIA: RANDOMIZED, CONTROLLED, ADAPTIVE CROSSOVER POLYSOMNOGRAPHY STUDY
    Herring, W. J.
    Budd, K. S.
    Hutzelmann, J.
    Snyder, E.
    Snavely, D.
    Liu, K.
    Lines, C.
    Michelson, D.
    Roth, T.
    [J]. SLEEP, 2010, 33 : A199 - A199
  • [4] THE SINGLE DOSE PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) PROFILES OF SUVOREXANT (MK-4305), A DUAL OREXIN RECEPTOR ANTAGONIST, IN HEALTHY MALE SUBJECTS
    Sun, H.
    Kennedy, D.
    Lewis, N.
    Laethem, T.
    Yee, K.
    Li, X.
    Hoon, J.
    Van Bortel, L.
    Rosen, L.
    Chodakewitz, J.
    Wagner, J.
    Murphy, G.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S29 - S29
  • [5] Electroencephalographic Power Spectral Density Profile of the Orexin Receptor Antagonist Suvorexant in Patients with Primary Insomnia and Healthy Subjects
    Ma, Junshui
    Svetnik, Vladimir
    Snyder, Ellen
    Lines, Christopher
    Roth, Thomas
    Herring, W. Joseph
    [J]. SLEEP, 2014, 37 (10) : 1609 - 1619
  • [6] Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #1)
    Connor, K.
    Budd, K.
    Snavely, D.
    Liu, K.
    Hutzel-Mann, J.
    Benca, R.
    Krystal, A.
    Roth, T.
    Michelson, D.
    Herring, W. J.
    [J]. JOURNAL OF SLEEP RESEARCH, 2012, 21 : 97 - 97
  • [7] Efficacy and safety of suvorexant, an orexin receptor antagonist, in patients with primary insomnia: a 3-month phase 3 trial (trial #2)
    Ivgy-May, N.
    Leibensperger, H.
    Froman, S.
    Hutzelmann, J.
    Snavely, D.
    Snyder, E.
    Liu, K.
    Walsh, J.
    Roth, T.
    Michelson, D.
    Herring, W. J.
    [J]. JOURNAL OF SLEEP RESEARCH, 2012, 21 : 351 - 352
  • [8] Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials
    Herring, W. Joseph
    Connor, Kathleen M.
    Snyder, Ellen
    Snavely, Duane B.
    Zhang, Ying
    Hutzelmann, Jill
    Matzura-Wolfe, Deborah
    Benca, Ruth M.
    Krystal, Andrew D.
    Walsh, James K.
    Lines, Christopher
    Roth, Thomas
    Michelson, David
    [J]. JOURNAL OF CLINICAL SLEEP MEDICINE, 2016, 12 (09): : 1215 - 1225
  • [9] Clinical Trial Design for Assessment of the Orexin Receptor Antagonist Suvorexant in the Treatment of Insomnia in Patients with Alzheimer's Disease
    Herring, W. Joseph
    Snyder, Ellen
    Bliwise, Donald
    Ancoli-Israel, Sonia
    Budd, Kerry
    Hutzelmann, Jill
    Dam, Tien
    Michelson, David
    [J]. NEUROLOGY, 2017, 88
  • [10] DESIGN OF A CLINICAL TRIAL FOR ASSESSING THE OREXIN RECEPTOR ANTAGONIST SUVOREXANT IN TREATING INSOMNIA IN PATIENTS WITH ALZHEIMER'S DISEASE
    Herring, W. J.
    Snyder, E.
    Bliwise, D.
    Ancoli-Israel, S.
    Budd, K.
    Hutzelmann, J.
    Dam, T.
    Michelson, D.
    Swartz, J.
    [J]. SLEEP MEDICINE, 2017, 40 : E321 - E322
12345